NCT06164704: An ongoing trial by Upstream Bio Inc.
This trial is ongoing. It must report results 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06164704 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 18, 2023 |
| Completion date | July 7, 2025 |
| Required reporting date | July 7, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |